ValiRx PLC

EAJF

Company Profile

  • Business description

    ValiRx PLC is a UK-based biopharmaceutical and life sciences company focused on advancing cutting-edge therapies in healthcare. The Company mainly engages in developing technologies and products in oncology therapeutics and diagnostics, with a focus on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It develops therapeutics across fields in oncology and has a portfolio of products in the pipeline, including GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in different stages of development.

  • Contact

    D6 Thane Road
    MediCity Nottingham
    NottinghamNG90 6BH
    GBR

    T: +44 1157840026

    E: [email protected]

    https://www.valirx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    11

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,997.30168.10-1.83%
CAC 408,272.2479.76-0.95%
DAX 4026,359.87238.77-0.90%
Dow JONES (US)51,608.17739.38-1.41%
FTSE 10010,795.0986.46-0.79%
HKSE23,508.17245.67-1.03%
NASDAQ24,509.76626.52-2.49%
Nikkei 22558,860.43801.59-1.34%
NZX 50 Index14,306.963.190.02%
S&P 5007,416.59145.08-1.92%
S&P/ASX 2008,883.20161.50-1.79%
SSE Composite Index3,584.5817.99-0.50%

Market Movers